Gastroesophageal Reflux Disease (GERD) Market by Route of Administration, Type, and Geography - Forecast and Analysis 2023-2027

Gastroesophageal Reflux Disease (GERD) Market Forecast 2023-2027:

The Gastroesophageal Reflux Disease (GERD) Market size is estimated to grow by USD 908.49 million between 2022 and 2027.  The size of the market is expected to increase at a CAGR of 3.4%. Market players are persistently focussing on launching new products and medicines to overcome the disease. Alongside industry players, the government is also increasing awareness and increasing the number of approvals for GERD treatment. For instance, in September 2022, the United States Food and Drug Administration (FDA) approved the use of omeprazole and sodium bicarbonate by Azurity Pharmaceuticals, Inc. for oral suspension to treat benign gastric ulcers and GERD. Another popular way of treating GERD is the usage of PPIs.These types of treatments will have a positive impact on the market growth as these treatments are readily available, and have high efficacy rates.

What will be the Size of the Gastroesophageal Reflux Disease (GERD) Market During the Forecast Period?

To learn more about this report, Request Free Sample

Most people suffer from gastroesophageal reflux disease due to factors such as poor lifestyle, overdose of medicines and dietary supplements, and obesity. These reasons are influencing the growth of the market. Additionally, increasing awareness of GERD, and the growth of E-commerce platforms are also driving market growth. During the pandemic, in 2020 the market spiked as there was a high requirement from the customer's end. 

GERD Market Segmentation by Route of Administration, Type, and geography

Oral Route 

In this, the oral segment is leading the market growth.?The?oral segment?was valued at?USD 3,723.39 million?in 2017 and continues to grow during the forecast period. 

The oral route of administration is the most commonly used route for GERD medication. The oral route is preferred to administer GERD drugs over other methods as it is a safe, non-invasive, cost-effective, and easy-to-use method.?The oral drug route of administration segment includes GERD drugs that can be administered in the form of capsules, tablets, syrups, solutions, and suspensions. The growth of the segment is accelerating at a moderate pace owing to the ease of usage and an increasing number of government approvals for oral GERD treatment.? 

Get a glance at the market contribution of various segments Request a PDF Sample

Parenteral Route 

The parenteral route of administration segment includes the injectable drugs that bypass the gastrointestinal system and are administered into muscles. This segment is expected to grow at the fastest rate during the forecast period due to its growing preference from end-users. Utilizing intramuscular injection (IM), drugs are injected deep within layers of muscles. Since the large muscles have strong blood flow, the drug is injected fast, bypassing the first-pass metabolism, and enters systemic circulation before entering the targeted area of action.? 

Type Analysis 

Based on the type segment the?global gastroesophageal reflux disease market is classified into?antacids, PPI, H2 receptor antagonist drugs, and pro-kinetic drugs.? 

Antacids 

Antacids are medications that help neutralize stomach acid.?They can be used to treat symptoms of excess stomach acid, such as acid reflux, that include vomiting, bitter taste, persistent dry cough, pain when the patient lies down, trouble in swallowing (dysphagia), heartburn, and dyspepsia.? 

PPI 

PPIs are drugs that act by irreversibly inhibiting the H+ of the proton pump (H+/K+ ATPase) found in the parietal cells of the gastric mucosa. The proton pump is the terminal stage of gastric acid secretion and is responsible for secreting acid into the gastric lumen. The PPIs target this stage and reduce the secretion of gastric acid through an irreversible reaction.? 

H2 Receptor Antagonist Drug 

H2 receptor antagonist drugs act by blocking the action of histamine receptors present in the parietal cells by reducing the production of acids.?These drugs decrease both basal and food-stimulated secretion of acids such as ranitidine and cimetidine.?The global H2 receptor antagonist segment will grow steadily owing to the increased preference for GERD treatments during the forecast period.? 

Prokinetic agents 

Prokinetic agents?are used to treat constipation, heartburn, abdominal discomfort, bloating, nausea, vomiting, and a variety of gastrointestinal illnesses, including irritable bowel syndrome, gastritis, gastroparesis, and functional dyspepsia. The prokinetic drugs market will grow owing to factors such as higher clinical approval by regulatory bodies such as the US FDA for worldwide drug consumption and an increase in adult and pediatric motility disorders such as gastroparesis, GERD, and esophageal achalasia.? 

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request PDF Sample now!

The high prevalence of GERD for which GERD drugs are predominantly used, the increasing preference for OTC medications, and the practice of self-medication among the population drive the growth of the market in the region. For instance, as per International Foundation for Gastrointestinal Disorders (IFFGD)s report in 2021, the prevalence of GERD in the region was estimated to be 20% in North America.

The market in North America is expected to grow at a slow rate during the forecast period owing to market saturation. However, the high per capita income of countries such as the US and Canada encourages spending on healthcare, thereby sustaining market growth.

To know more about segments Download Report Sample

Key Players in GERD Market 

There is high competition in the gastroesophageal reflux disease market. Among several market players, the organization Pfizer Inc. stands out among the competitors due to technological innovation and its on-point marketing strategy. 

Pfizer Inc. a renowned industry player in the healthcare market offers GERD drugs such as omeprazole delayed-release tablets. The company is also involved in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• Bayer AG
• Alkem Laboratories Ltd.
• Apotex Inc.
• AstraZeneca Plc
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• Eisai Co. Ltd.
• Fresenius SE and Co. KGaA
• GlaxoSmithKline Plc
• iNova Pharmaceuticals
• Johnson and Johnson
• Lupin Ltd.
• Perrigo Co. Plc
• SRS Life Sciences Pte. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• The Procter and Gamble Co.
• Abbott Laboratories

Technavio’s report consists of a holistic analysis of the key development analysis,  development stage,  pipeline analysis,  FDA approval, market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge. 

Market: Key Drivers, Trends, Challenges

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year and the key drivers, trends, and challenges. 

Key Market Driver

The rise of the geriatric population will significantly drive the gastroesophageal reflux disease market growth. As people get older, the likelihood of experiencing acidity and heartburn tends to increase. The lower end of the esophagus features a valve that is responsible for keeping acid within the stomach. However, this valve or sphincter tends to relax as a person ages, allowing acid to flow back or reflux, resulting in heartburn. Furthermore, the digestive system slows down with age, which can also contribute to acidity. GERD can also cause heartburn, and age is a significant factor in the development of various disorders, including GERD. Therefore, the expanding aging population is a crucial factor driving the global market.

The advancement of healthcare and the availability of improved treatment options for various illnesses have resulted in an increase in life expectancy worldwide. The geriatric population, particularly in developed economies, is growing rapidly. For example, according to the United States Census Bureau (USCB), in 2022, approximately 56 million individuals aged 65 and over resided in the United States, with this number projected to reach 73 million by 2030. The elderly population is more susceptible to health conditions such as GERD. As a result, the demand for GERD drugs is projected to increase worldwide due to the rising geriatric population, contributing to market expansion during the forecast period.

Significant Market Trends

The dominant trend in the market is the growing e-commerce industry. The market is witnessing a surge in online transactions, primarily due to the dominance of over-the-counter (OTC) drugs that do not require prescriptions. With the convenience of online shopping and the absence of a need for extensive product knowledge, consumers can easily purchase these drugs online. Retailers are making efforts to enhance the online shopping experience by providing better online education and targeted marketing, which has contributed to the increased popularity of e-commerce retailing. The improved shopping experience has made consumers more comfortable with buying products online, leading to the emergence of various organizations that aim to tap into this market potential, thereby driving the market growth.

Moreover, the strong viability of e-commerce channels has further boosted the sales of GERD drugs. Online retailers offer free access to various online offers, and giants like Amazon provide features such as different billing and shipping addresses, enabling customers to conveniently send medication to different geographic locations. Such online facilities encourage consumers to buy medicines online, contributing to the growth of the gastroesophageal reflux disease market.

Major Market Challenge

Increased preference for complementary and alternative medicine CAM is the major challenge in the gastroesophageal reflux disease market. These treatments aim to ease disease symptoms. According to the CancerQuest report, CAMs are becoming increasingly popular among people in the US in 2021, with around 75% of the people in the US trying these therapies at least once in their life and with growing awareness of CAM treatments for GERD, the trend is preferred in many countries nowadays to avoid medication and involve physical exercises and dietary changes.

The commonly used CAMs for the treatment of GERD are acupuncture, massage, tai chi, herbs, and supplements, as well as mind and body therapies such as yoga, meditation, exercise, and relaxation therapy. They also include alternative therapies such as homeopathy and naturopathy. For instance, herbs such as chamomile, marshmallow, and slippery elm are used to reduce the symptoms of GERD. Similarly, vitamins A, C, and E and minerals like magnesium and zinc are also used for relief from GERD symptoms. Thus, the increasing adoption of CAMs for treating GERD will restrict the growth of the market during the forecast period.

To know more about drivers, trends, and challenges Download Report Sample

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides a market growth analysis analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Route Of Administration Outlook (USD Million, 2017 - 2027)
  • Oral
  • Parenteral

• Type Outlook (USD Million, 2017 - 2027)
  • Antacid
  • PPI
  • H2 receptor antagonist drugs
  • Pro-Kinetic drugs

• Region Outlook (USD Million, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina
    • Rest of the Middle East & Africa

Market Analyst Overview

The market addresses the challenges posed by heartburns through an array of innovative devices designed for disease management. These devices, categorized as minimally invasive, provide effective alternatives to traditional approaches. Alongside devices, acid-reducing or neutralizing drugs play a crucial role in managing GERD symptoms.

Seeking the expertise of healthcare professionals, individuals consult primary care physicians (PCPs) and gastroenterologists for comprehensive care. However, refractory symptoms may necessitate specialized interventions. GERD, being a chronic disease, not only affects the well-being of individuals but also exerts a significant economic impact through direct costs associated with medical care. The market continues to evolve, driven by advancements in treatment modalities, reflecting the commitment to enhancing patients' quality of life and addressing the economic burden of GERD.

GERD Market Scope
Report Coverage	Details
Page number	166
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 3.4%
Market growth 2023-2027	USD  908.49 million
Market structure	Fragmented
YoY growth 2022-2023(%)	3.3
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Bayer AG, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, iNova Pharmaceuticals, Johnson and Johnson, Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., The Procter and Gamble Co., and Abbott Laboratories
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this GERD Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the market in focus on the parent market
• Detailed market research report analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Vendor landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on vendor position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and the Rest of World (ROW)
• A thorough market growth and forecasting analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market research and growth analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch